Several factors contributed to the less than optimal number of IVIs of anti-VEGF in the real-world setting, including patient-related factors such as financial concerns, transport issues, poor motivation, or inconvenience due to other diabetes-related comorbidities. The gene discussed is VEGFA; the disease is diabetes mellitus.